Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
As you know I am reviewing my pension as discussed HERE. As such I am chatting to various CEOs who I have backed and yesterday evening I had a long chat with Stuart Ashman of Skinbiotherapeutics (SBTX). He is not a bluffing promoter but, I believe, a sober and grounded chap. I came away from the call just incredibly excited. I explain why the share price is where it is but also why this could within a couple of years be a 10 bagger but it could equally be a 20 bagger. Certainly any free cash within my SIPP will, even at twice today’s price be going into this stock. And if I am right there is a clear implication for Optibiotix (OPTI) so I am not selling any shares in it either. Footnote/correction. There are not 2 million psoriasis sufferers worldwide as per podcast but 120 million. I can’t say that weakens the case!
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.